CONSULTANCY

Initial Terms of Reference

This consultancy is requested by:

<table>
<thead>
<tr>
<th>Unit:</th>
<th>Global Malaria Strategy &amp; Agenda Setting</th>
</tr>
</thead>
<tbody>
<tr>
<td>Department:</td>
<td>Global Malaria Programme</td>
</tr>
</tbody>
</table>

1. **Purpose of the Consultancy**

The purpose of the consultancy is to support the activities of the vaccine research and product development team within the Immunization, Vaccines and Biologicals (IVB) department in collaboration with the Global Malaria Programme (GMP). The World Health Organization (WHO) aims to express preferences about the next generation malaria vaccine preferred product characteristics (PPC) and research and development avenues to accelerate the development, programmatic suitability and future impact of malaria vaccines. WHO preferences in research are expressed following consensus-building consultation processes and input from experts and stakeholders. A Malaria Vaccine Advisory Committee (MALVAC) has been set up to provide expert assistance to WHO.

2. **Background**

WHO IVB provides leadership on research activities to develop new vaccines or improve existing vaccines against diseases of public health importance and to facilitate their introduction and use. The vaccine development group within IVR focuses on facilitation of early stage research and development in disease areas with no available vaccines or sub-optimal vaccines, and where research is needed to optimize public health impact of underutilized existing vaccines and vaccines delivery innovations. WHO/GMP is responsible for coordinating WHO’s global efforts to control and eliminate malaria. WHO IVB and GMP collaborate on malaria vaccine related topics.

No vaccine is currently available to prevent malaria and its complications. RTS,S/AS01 has received a favourable European Medicines Agency (EMA) scientific opinion and is undergoing pilot implementation and evaluation in three African countries, as called for by WHO. Next generation malaria vaccines able to provide a higher level of protection and reduce transmission will be required. The Malaria Vaccine Advisory Committee (MALVAC) has been established for expert input to help WHO IVR and GMP articulate its coordinated vision, product preferences and recommendations on malaria vaccine research and development (R&D) priorities and pathways. WHO plans to renew its recommendations in order to accelerate product development and prepare for future policy decisions.

3. **Planned timelines** (subject to confirmation)

   - Start date: 01/05/2020
   - End date: 31/01/2021

4. **Work to be performed**

   **Output 1:** Malaria vaccine PPC development
   
   Deliverable 1.1: Draft Preferred Product Characteristics (PPC) for agreed malaria vaccine use case scenarios for review and discussion at a MALVAC working group meeting.
Deliverable 1.2: Organize MALVAC working group meeting to develop the malaria vaccine PPCs for specific use cases.

Output 2: Malaria vaccine landscape analysis
Deliverable 2.1: Prepare an updated malaria vaccine landscape analysis for publication on the WHO health R&D observatory.

Output 3: Malaria vaccine research and development technical roadmap
Deliverable 3.1: Develop a first draft of an updated WHO Technical R&D Roadmap, including key considerations for clinical development pathways, for next generation malaria vaccines

Output 4: MALVAC coordination
Deliverable 4.1: Support management of MALVAC through budget and activities planning and reporting.

5. Technical Supervision
The selected Consultant will work on the supervision of:

<table>
<thead>
<tr>
<th>Responsible Officer:</th>
<th>Dr David Schellenberg, Science Advisor, GMP/Global Malaria Strategy &amp; Agenda Setting Team (STR)</th>
<th>Email: <a href="mailto:schellenbergd@who.int">schellenbergd@who.int</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Manager:</td>
<td>Dr Pedro Alonso, Director, GMP (STR team lead, a.i.)</td>
<td>Email: <a href="mailto:alonsop@who.int">alonsop@who.int</a></td>
</tr>
</tbody>
</table>

6. Specific requirements
- Qualifications required:
  - Bachelor’s degree in epidemiology, public health, a relevant science, or related field (preference Master’s degree or PhD)
  - Project management qualification or experience an advantage

- Experience required:
  - At least three (3) years of experience in a product development partnership, private industry, public health organisation, or academia
  - Experience in the field of project management/product development related to vaccination

- Skills / Technical skills and knowledge:
  - Broad understanding of malaria, clinical trials, product development, regulatory and policy pathways
  - Capability to interact with technical experts in public health organisations, governments, academia, and industry, with respect to vaccination
  - High quality scientific writing, reporting skills and strong experience in developing and editing proposals, documents, technical reports and communication materials
  - Results-oriented management style, self-starter and excellent consultative and organization skills
  - Demonstrated collaborative mindset, adaptable to team environment, willingness to work independently.

- Language requirements:
  - Excellent oral and written communication skills in English

7. Place of assignment
Geneva, Switzerland
8. Medical clearance
The selected Consultant will be expected to provide a medical certificate of fitness for work.

9. Travel
Up to four (4) international trips for technical meetings may be required. Dates and location to be confirmed.

All travel arrangements will be made by WHO – WHO will not be responsible for tickets purchased by the Consultant without the express, prior authorization of WHO. While on mission under the terms of this consultancy, the Consultant will receive subsistence allowance.

Visas requirements: it is the consultant’s responsibility to fulfil visa requirements and ask for visa support letter(s) if needed.